Why Healthcare Providers Choose the 4Kscore^® Test

To Assess the Patient’s Probability of Aggressive Prostate Cancer 

Two US based, prospective validation studies, including a study performed at Veterans Health Administration facilities involving a predominantly African American population, resulted in combined intended use population of 937 subjects. 

• At a cut-point of 5.0, the 4Kscore Test performance characteristics for the detection of Gleason Score (GS) ≥ 7 (aggressive prostate cancer) show:
  • Sensitivity of 96.9% and Negative Predictive Value (NPV) of 95.9% with DRE information
  • Sensitivity 97.6% and NPV of 96.4% if DRE information is unavailable
• Resulted in a meaningful reduction in avoidable prostate biopsies.
• Both studies demonstrated that the 4Kscore Test did not miss any Gleason 8 and higher on biopsy using the 4Kscore result at cut point of 5.0.
• The 4Kscore Test is included in the current NCCN and AUA prostate cancer early detection guidelines.^{1, 2}